Profile data is unavailable for this security.
About the company
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
- Revenue in SEK (TTM)3.54bn
- Net income in SEK-3.80bn
- Incorporated1989
- Employees1.12k
- LocationVitrolife ABGustaf Werners gata 2, Vastra FrolundaGOETEBORG 421 32SwedenSWE
- Phone+46 317218000
- Fax+46 317218099
- Websitehttps://www.vitrolife.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenio Group Oyj | 1.10bn | 215.80m | 10.49bn | 216.00 | 48.05 | 9.22 | 40.24 | 9.55 | 0.7205 | 0.7205 | 3.66 | 3.76 | 0.7069 | 5.50 | 7.60 | 447,574.10 | 13.90 | 14.33 | 16.77 | 17.90 | 51.01 | 50.73 | 19.66 | 21.13 | 1.79 | 28.49 | 0.1521 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
| Arjo AB (publ) | 11.23bn | 536.00m | 11.08bn | 6.94k | 22.15 | 1.49 | 7.16 | 0.9867 | 1.97 | 1.97 | 41.21 | 29.20 | 0.6957 | 4.40 | 6.51 | 1,651,221.00 | 3.31 | 3.55 | 4.51 | 5.55 | 43.68 | 44.01 | 4.76 | 5.41 | 0.6657 | 4.01 | 0.4123 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
| ChemoMetec A/S | 620.74m | 207.41m | 11.37bn | 173.00 | 54.81 | 13.21 | 48.50 | 18.31 | 7.83 | 7.83 | 23.44 | 32.48 | 0.6112 | 0.745 | 6.97 | 2,357,630.00 | 20.42 | 27.96 | 24.40 | 35.10 | 78.80 | 79.57 | 33.41 | 35.02 | 3.76 | -- | 0.0073 | 144.08 | -8.22 | 18.37 | -23.72 | 26.64 | 9.97 | -- |
| Biotage AB | 2.09bn | 250.00m | 14.49bn | 667.00 | 57.97 | 3.82 | 33.38 | 6.95 | 3.12 | 3.12 | 26.05 | 47.36 | 0.4237 | 1.70 | 6.60 | 3,094,956.00 | 5.08 | 10.74 | 5.87 | 12.77 | 62.90 | 61.40 | 11.98 | 15.75 | 1.14 | 16.13 | 0.0628 | 40.11 | 19.54 | 15.50 | -8.21 | 7.97 | 14.05 | 1.30 |
| Xvivo Perfusion AB | 698.73m | 120.74m | 15.50bn | 152.00 | 124.66 | 7.65 | 81.80 | 22.18 | 3.95 | 3.95 | 22.69 | 64.28 | 0.3441 | 1.22 | 4.48 | 4,367,031.00 | 5.95 | 1.24 | 6.45 | 1.33 | 74.16 | 73.14 | 17.28 | 4.76 | 3.27 | -- | 0.0133 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| Embla Medical hf | 8.37bn | 623.80m | 20.03bn | 4.00k | 32.21 | 2.61 | 17.24 | 2.39 | 0.9557 | 0.9557 | 12.81 | 11.80 | 0.5639 | 2.20 | 6.40 | 1,375,117.00 | 4.21 | 4.06 | 4.97 | 4.76 | 61.80 | 62.47 | 7.47 | 6.91 | 1.12 | 5.54 | 0.4205 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Elekta AB (publ) | 18.12bn | 1.13bn | 25.32bn | 4.57k | 23.19 | 2.45 | 10.97 | 1.40 | 2.96 | 2.96 | 47.38 | 28.01 | 0.5822 | 3.16 | 2.89 | 3,903,469.00 | 3.65 | 4.19 | 6.53 | 7.51 | 36.76 | 39.03 | 6.27 | 7.37 | 0.7425 | 3.91 | 0.4196 | 68.60 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
| Vitrolife AB | 3.54bn | -3.80bn | 32.21bn | 1.12k | -- | 2.46 | -- | 9.11 | -28.06 | -28.06 | 26.11 | 96.72 | 0.1836 | 3.65 | 6.16 | 3,276,182.00 | -19.72 | -4.57 | -20.43 | -4.78 | 57.48 | 58.38 | -107.41 | -21.89 | 2.43 | 8.48 | 0.1379 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Sectra AB | 1.81bn | 447.23m | 47.86bn | 1.22k | 113.90 | 30.79 | 87.51 | 26.44 | 2.32 | 2.32 | 9.40 | 8.59 | 0.6136 | -- | 3.63 | 1,503,436.00 | 15.16 | 15.75 | 28.08 | 29.52 | 47.01 | 64.95 | 24.71 | 19.59 | -- | -- | 0.027 | 0.00 | 26.84 | 4.06 | 14.25 | 16.58 | 48.37 | -- |
| Ambu A/S | 8.01bn | 684.85m | 48.53bn | 4.82k | 80.23 | 6.28 | 38.65 | 6.06 | 1.69 | 1.69 | 19.80 | 21.60 | 0.7459 | 2.18 | 7.17 | 1,140,165.00 | 6.38 | 3.81 | 7.37 | 4.62 | 58.88 | 59.37 | 8.55 | 5.43 | 1.51 | 74.38 | 0.0961 | 22.89 | 7.45 | 12.88 | 80.65 | -13.00 | 6.67 | -- |
| Getinge AB | 33.33bn | 2.58bn | 56.88bn | 11.89k | 23.60 | 1.94 | 12.57 | 1.71 | 9.48 | 9.48 | 122.36 | 115.57 | 0.6168 | 2.48 | 7.04 | 2,839,084.00 | 4.81 | 5.31 | 6.35 | 6.98 | 46.27 | 47.83 | 7.79 | 8.69 | 0.6455 | 8.99 | 0.2136 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| Demant A/S | 34.05bn | 4.03bn | 95.09bn | 21.50k | 23.58 | 6.52 | -- | 2.79 | 11.98 | 10.92 | 101.23 | 43.36 | 0.7192 | 2.03 | 5.68 | 1,034,778.00 | 8.52 | 8.27 | 11.68 | 13.23 | 75.45 | 74.14 | 11.85 | 11.34 | 1.06 | 5.58 | 0.6244 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
Data as of Sep 19 2024. Currency figures normalised to Vitrolife AB's reporting currency: Swedish Krona SEK
23.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AMF Fonder ABas of 04 Jan 2024 | 6.90m | 5.09% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 4.76m | 3.52% |
| Swedbank Robur Fonder ABas of 30 Aug 2024 | 4.74m | 3.50% |
| Handelsbanken Fonder ABas of 31 Aug 2024 | 2.98m | 2.20% |
| SEB Investment Management ABas of 30 Aug 2024 | 2.77m | 2.04% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 2.33m | 1.72% |
| Cliens Kapitalf�rvaltning ABas of 31 Dec 2023 | 2.28m | 1.68% |
| Tredje AP-fondenas of 31 Aug 2023 | 1.74m | 1.29% |
| Norges Bank Investment Managementas of 31 Aug 2023 | 1.53m | 1.13% |
| L�nsf�rs�kringar Fondf�rvaltning ABas of 31 Aug 2024 | 1.41m | 1.04% |
More ▼
Data from 30 Jun 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
